Goldman Sachs’s PharMerica Corporation PMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-420,462
Closed -$12.3M 6909
2017
Q3
$12.3M Buy
420,462
+379,197
+919% +$10.6M ﹤0.01% 2385
2017
Q2
$1.08M Sell
41,265
-38,529
-48% -$947K ﹤0.01% 4383
2017
Q1
$1.87M Sell
79,794
-31,084
-28% -$767K ﹤0.01% 3811
2016
Q4
$2.79M Buy
110,878
+73,667
+198% +$1.86M ﹤0.01% 3539
2016
Q3
$1.04M Sell
37,211
-115,021
-76% -$2.95M ﹤0.01% 4359
2016
Q2
$3.75M Sell
152,232
-16,821
-10% -$417K ﹤0.01% 3100
2016
Q1
$3.74M Sell
169,053
-16,884
-9% -$449K ﹤0.01% 2938
2015
Q4
$6.51M Sell
185,937
-13,931
-7% -$436K ﹤0.01% 2592
2015
Q3
$5.69M Buy
199,868
+172,182
+622% +$5.78M ﹤0.01% 2776
2015
Q2
$922K Sell
27,686
-145,858
-84% -$4.48M ﹤0.01% 4611
2015
Q1
$4.89M Buy
173,544
+160,403
+1,221% +$3.99M ﹤0.01% 2928
2014
Q4
$272K Sell
13,141
-169,611
-93% -$4.03M ﹤0.01% 5888
2014
Q3
$4.46M Sell
182,752
-12,273
-6% -$325K ﹤0.01% 3130
2014
Q2
$5.58M Sell
195,025
-21,203
-10% -$590K ﹤0.01% 2923
2014
Q1
$6.05M Sell
216,228
-65,905
-23% -$1.62M ﹤0.01% 2807
2013
Q4
$6.07M Buy
282,133
+63,863
+29% +$1.16M ﹤0.01% 2862
2013
Q3
$2.9M Buy
218,270
+107,043
+96% +$1.44M ﹤0.01% 3530
2013
Q2
$1.54M Buy
+111,227
New +$1.58M ﹤0.01% 3970

Goldman Sachs's PMC Position: Q4 2017 in Review

Goldman Sachs sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 420,462 shares — an estimated $12.3M sold.

Goldman Sachs first reported a position in PMC in Q2 2013 and held it in 18 quarters. The position peaked at $12.3M in Q3 2017. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.

  • Goldman Sachs reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
  • Goldman Sachs sold 420,462 PharMerica Corporation shares in Q4 2017, an estimated $12.3M.
  • Goldman Sachs first reported a position in PharMerica Corporation in Q2 2013 and held it in 18 quarters.
  • Goldman Sachs's PharMerica Corporation position peaked at $12.3M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.